Healthcare / BiotechnologyKOSDAQ
$11320.00
-370.00 (-3.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-6.6B · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.09T
P/E
N/A
•EV/EBITDA
N/A
•ROE
-20.0%
↓Gross Margin
6.9%
↓Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-23.5%
FCF CAGR
—
FCF margin
-1058.9%
FCF / Net income
1.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.52B · net income $-22.13B · FCF $-37.24B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.52B | $3.52B | $15.05B | $9.48B | $7.85B |
| Net Income | $-22.13B | $-22.13B | $-6.93B | $-14.50B | $-15.81B |
| EBITDA | $-18.36B | $-18.36B | $-3.94B | $-12.75B | $-14.38B |
| EPS | -0.21 | -0.21 | -0.27 | -171.78 | -189.19 |
| Gross Margin | 6.9% | 6.9% | 78.8% | 53.2% | 34.2% |
| Operating Margin | -516.3% | -516.3% | 5.5% | -103.2% | -335.1% |
| Net Margin | -629.1% | -629.1% | -46.0% | -152.9% | -201.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.67 | 0.12 | 0.11 |
| Current Ratio | 2.40 | 2.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-37.24B | $-37.24B | $87.5M | $-6.60B | $-18.09B |
| Returns | |||||
| ROE | -20.0% | -20.0% | -17.6% | -32.0% | -27.1% |
| Valuation | |||||
| P/B | 9.82 | 9.82 | 15.04 | 21.32 | 19.51 |
| Growth & Yield | |||||
| Revenue Growth | -76.6% | -76.6% | 58.7% | 20.8% | — |
| EPS Growth | 22.2% | 22.2% | 99.8% | 9.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+95.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.27 → -0.21
Residual
+95.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.